These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 19833685)
1. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. Yildiz R; Kalender ME; Dane F; Sevinc A; Gumus M; Camci C; Alici S; Kaya AO; Yaman E; Ozturk B; Coskun U; Benekli M; Uncu D; Buyukberber S J Oncol Pharm Pract; 2010 Sep; 16(3):173-8. PubMed ID: 19833685 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Zhong H; Zhang Y; Ma S; Ying JE; Yang Y; Yong D; Hang X; Sun Q; Zhong B; Wang D Anticancer Drugs; 2008 Nov; 19(10):1013-8. PubMed ID: 18827567 [TBL] [Abstract][Full Text] [Related]
8. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159 [TBL] [Abstract][Full Text] [Related]
9. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799 [TBL] [Abstract][Full Text] [Related]
13. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287 [TBL] [Abstract][Full Text] [Related]
14. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Kim H; Park JH; Bang SJ; Kim DH; Cho HR; Kim GY; Min YJ Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Sym SJ; Chang HM; Kang HJ; Lee SS; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2008 Dec; 63(1):1-8. PubMed ID: 18288477 [TBL] [Abstract][Full Text] [Related]
17. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer. Gu Y; Shu Y; Xu Q Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761 [TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]